A Study on Predictive Models and Clinical Outcome of Radiation Pneumonitis

Recruiting Observational Study
Radiation Pneumonitis
No Placebo Group Every participant receives an active treatment — no one gets a placebo. No Study Drug Researchers observe your health over time — no experimental treatment is given.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 and older
Sex
Any
Study type
Observational
Participants needed
300 (estimated)
Sponsor
Huazhong University of Science and Technology · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
Radiation pneumonitis is the main dose-limiting toxicity of thoracic radiotherapy, which can affect life quality, survival, and the tumor-controlling effects of patients receiving thoracic radiotherapy. The purpose of this study is to: * Identify biomarkers including serum proteins, gene expression, genetic changes, and epigenetic modifications that determine radiation pneumonitis. * Investigate…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: 1. Clinical diagnosis of lung cancer by histology 2. Radiation dose at least 45 Gy 3. Karnofsky \>60 4. Age\>18 5. Life expectancy of at least 6 months Exclusion Criteria: 1. Previous thoracic irradiation 2. Severe cardiopulmonary diseases
Contacts

Xianglin Yuan, PhD

+8613667241722

yuanxianglin@hust.edu.cn

CONTACT

Lingyan Xiao, MD

+8615971474885

lingyan.xiao123@gmail.com

CONTACT